Special Issue

Recent Advances in Antimicrobial Nanodrugs 2023

Message from the Guest Editor

Microbial infections have always posed a threat to public health, and the situation is becoming worse as some strains of these microorganisms develop drug resistance to drugs such as conventional antibiotics. With the rapid development of nanotechnology and nanomaterials, an increasing number of nanodrugs capable of fighting against various microorganisms have been designed and prepared. The journal Pharmaceuticals invites both original articles and reviews regarding the use of nanomaterials and nanodrugs for antimicrobial applications. The related topics include: metal-based nanodrugs for antimicrobial applications, metal-free nanodrugs for antimicrobial applications, and hybrid nanodrugs for antimicrobial applications. We also welcome papers that investigate the interaction mechanisms between nanomaterials/nanodrugs and microorganisms (bacteria, fungi, and viruses). The collection of manuscripts will be published as a Special Issue of the journal.

Guest Editor

Prof. Dr. Fu-Gen Wu

State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, 2 Sipailou Road, Nanjing 210096, China

Deadline for manuscript submissions

closed (20 August 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/145294

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

